Targeted small molecule therapeutics for treating cancer
Array (NASDAQ: ARRY) is a drug discovery and development company focusing on first-in-class small molecule therapeutics for cancer. The company has completed partnerships with a number of leading biopharmaceutical companies, including fellow Frazier portfolio company VentiRx. Array completed its IPO on NASDAQ in 2000.